Obsidian Therapeutics, Inc.
corporate_fare Company Profile
Obsidian Therapeutics, Inc. (NASDAQ:OBX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 5 items for OBX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 5 most recent items scored 7 or higher, the top rating is 9/10, with 2 rated 8 or above. Recent SEC coverage for OBX spans 10-Q, 8-K, 8-K/A.
Recent high-impact activity:
- Obsidian 10-Q: $50.7M Q3 Loss, $324.4M Cash Into 2H 2028, New Director
- Obsidian Posts Q3 Loss of $50.7M With $324.4M Cash and 67% ORR in Melanoma
- Obsidian's amsoki-cel Hits 67% Response Rate in Advanced Melanoma
- Obsidian Files Merger Financials: $350M PIPE Alleviates Going Concern
- Obsidian Therapeutics finalizes reverse merger with Galera, secures $350M PIPE, and debuts on Nasdaq as OBX
Financial Snapshot
Short Interest & Short Volume
3.94 days to coverFINRA reported short interest of 1,184,895 shares in OBX as of the October 30, 2026 settlement, a 9.6% increase from the prior period — about 3.9 days to cover at its recent average daily volume. On November 20, 2026, 44.0% of OBX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for OBX, detected from its recent SEC filings.
29.2M PIPE Shares Registered for Resale · Selling Stockholders Identified
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →